Research programme: peptide-based immunotherapeutics - InterK Peptide Therapeutics

Drug Profile

Research programme: peptide-based immunotherapeutics - InterK Peptide Therapeutics

Alternative Names: Compound A - InterK Peptide Therapeutics; Compound B - InterK Peptide Therapeutics; Lck activators - InterK Peptide Therapeutics; Peptide based therapeutics - InterK Peptide Therapeutics; Synthetic peptide sequences - InterK Peptide Therapeutics; Synthetic peptide-based compounds - InterK Peptide Therapeutics

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InterK Peptide Therapeutics
  • Class Anti-infectives; Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Lymphocyte specific protein tyrosine kinase p56(lck) stimulants; Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Infections

Most Recent Events

  • 01 Jun 2018 Immunogenicity data from a preclinical trial in Cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 13 Jul 2016 Preclinical trials in Cancer in Australia (unspecified route)
  • 13 Jul 2016 Preclinical trials in Infections in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top